Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01329900 Background | Aug 2011 → Jul 2019 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01329900 ↗ |
| Route | Subcutaneous | “G-CSF 6 mcg/kg subcutaneously twice a day on day 6” NCT01329900 ↗ |